TargetBeta
DHFR
dihydrofolate reductase · also DHFR1 · Dihydrofolate reductase family
3 programs in company-led studies act on DHFR, from 3 companies: 0 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 14117 running | GART, TYMS | ChEMBL |
| Methotrexaterule | Hoffmann-La Roche | phase 4 | 1308 running | – | ChEMBL |
| pralatrexaterule | Aurobindo Pharma | phase 4 | 192 running | RFC1 | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Arthritis, Juvenile, 1 program
- Arthritis, Psoriatic, 1 program
- Arthritis, Rheumatoid, 1 program
- Breast Neoplasms, 1 program
- Colorectal Neoplasms, 1 program
- Gout, 1 program
- Hematologic Neoplasms, 1 program
- Lymphoma, B-Cell, 1 program
- Lymphoma, T-Cell, Cutaneous, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026Methotrexate · Hoffmann-La Roche · phase 4 · NCT06239311
- Dec 2026Pemetrexed · Eli Lilly · phase 4 · NCT06943820
- Feb 2027pralatrexate · Aurobindo Pharma · phase 4 · NCT07036133
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.